No-reflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis.
OBJECTIVE
We assessed the relationship between fibrin clot properties and the no-reflow phenomenon after primary coronary intervention (PCI).


RESULTS
Epicardial blood flow was assessed by TIMI scale and corrected TIMI frame count (cTFC), and perfusion by TIMI Myocardial Perfusion Grade (TMPG) after PCI during ST-segment elevation myocardial infarction (STEMI). Fibrin clot permeability (K(s)) and susceptibility to lysis in assays using exogenous thrombin (t(50%)) and without thrombin (t(TF)) were determined in 30 no-reflow patients (TIMI < or = 2) and in 31 controls (TIMI-3) after uneventful 6 to 14 months from PCI. Patients with TIMI < or = 2 had lower K(s) by 18% (P<0.0001) and prolonged fibrinolysis by 33% for t(50%) (P<0.0001) and by 45% for t(TF) (P<0.0001). cTFC was correlated with K(s) (r=-0.56, P<0.0001), t(50%) (r=0.49, P<0.001), and t(TF) (r=0.54, P<0.001). K(s) increased in a stepwise fashion with TIMI flow (P<0.0001) and TMPG (P<0.0001), whereas both fibrinolysis times decreased with TIMI flow (P<0.0001 for both) and TMPG (P<0.01 for both). Multiple regression models showed that only K(s) and fibrinogen were independent predictors of cTFC (P<0.05 for both), TIMI < or = 2 flow (P<0.05 for both) and TMPG-0/1 (P<0.05 for both).


CONCLUSIONS
Survivors of myocardial infarction with a history of the no-reflow after PCI are characterized with more compact fibrin network and its resistance to lysis.
Zalewski
Jaroslaw
J
Institute of Cardiology, Jagiellonian University School of Medicine, and John Paul II Hospital, 80 Pradnicka Street, 31-202 Cracow, Poland. jzalewski@szpitaljp2.krakow.pl
Undas
Anetta
A
Godlewski
Jacek
J
Stepien
Ewa
E
Zmudka
Krzysztof
K
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D016022:Case-Control Studies; D017023:Coronary Angiography; D003326:Coronary Circulation; D003328:Coronary Thrombosis / Q000097:blood / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D004562:Electrocardiography; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis; D005500:Follow-Up Studies; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D010539:Permeability; D012107:Research Design; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D005337:Fibrin